Pipeline

Immuno-Oncology

HomePipelineImmuno-Oncology

Publications

Park E et al. The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation. PEGS Boston 2019

Download

Cancer Immuno-Oncology

Conditional 4-1BB Agonist: TAA (Tumor Associated Antigen)-Dependent 4-1BB Agonistic Effect

Conditional 4-1BB Agonist: TAA (Tumor Associated Antigen)-Dependent 4-1BB Agonistic Effect
좌우스크롤 Conditional 4-1BB Agonist: TAA (Tumor Associated Antigen)-Dependent 4-1BB Agonistic Effect
Asset, MOA, Note
좌우스크롤 Asset, MOA, Note

ABL’s Grabody™ T Platform is Engineered to Activate T cells in the Presence of TAA within the Tumor Microenvironment

ABL’s Grabody™ T BsAb is engineered to activate T-cells only at the Tumor Microenvironment

ABL’s Grabody™ T BsAb is engineered to activate T-cells only at the Tumor Microenvironment
ABL’s Grabody™ T BsAb is engineered to activate T-cells only at the Tumor Microenvironment
TAA Positive Cell Line/TAA Negative Cell Line
TAA Positive Cell Line/TAA Negative Cell Line

Anti-Tumor Effect with ABL’s Grabody™ T BsAbt

Anti-Tumor Effect with ABL’s Grabody™ T BsAb
Anti-Tumor Effect with ABL’s Grabody™ T BsAb

No Liver Toxicity with ABL’s Grabody™ T BsAb

No Liver Toxicity with ABL’s Grabody™ T BsAb
No Liver Toxicity with ABL’s Grabody™ T BsAb

ABL’s Grabody™ I Platform : Immunomodulatory Effects of PD-L1-based Dual Immune Checkpoint Blockade

Mechanism of Action of Grabody™ I

Mechanism of Action of Grabody™ I
Mechanism of Action of Grabody™ I

ABL’s Grabody™ I
ABL501 is a Dual Immune Checkpoint Blockade (PD-L1 & LAG-3)

ABL’s Grabody™ I
ABL’s Grabody™ I

Superior T Cell Activation than Combination by ABL’s Grabody™ I BsAb

Superior T Cell Activation than Combination by ABL’s Grabody™ I BsAb
Superior T Cell Activation than Combination by ABL’s Grabody™ I BsAb

Recent Immuno-Oncology & Bispecific Antibody Deals : "Early Stage & Bigger Deals"

The Latest Licensing Deals of Immuno-Oncology with Bispecific Technology

The latest Licensing Deals of Immuno-Oncology with Bispecific Technology
좌우스크롤 The latest Licensing Deals of Immuno-Oncology with Bispecific Technology